{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:42:09Z","timestamp":1783737729377,"version":"3.55.0"},"reference-count":47,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,10,1]]},"abstract":"<jats:p>The annual number of reported measles cases in the United States has declined from between 3 million and 4 million in the prevaccine era to &amp;lt;100 cases in association with the highest recorded immunization rates in history. Because of continued importation of measles into the United States, young children who are not vaccinated appropriately may experience more than a 60-fold increase in risk of disease. Unsubstantiated claims suggesting an association between measles vaccine and neurologic disorders have led to reduced vaccine use and a resurgence of measles in countries where immunization rates have declined below the level needed to maintain herd immunity. To address the possibility of worldwide control of measles, efforts to ensure high immunization rates among people in both developed and developing countries must be sustained.<\/jats:p>","DOI":"10.1542\/peds.2004-0440","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T18:57:26Z","timestamp":1097693846000},"page":"1065-1069","source":"Crossref","is-referenced-by-count":87,"title":["Measles Vaccines and the Potential for Worldwide Eradication of Measles"],"prefix":"10.1542","volume":"114","author":[{"given":"H. Cody","family":"Meissner","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Disease, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Strebel","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Orenstein","sequence":"additional","affiliation":[{"name":"Emory Vaccine Center, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,10,1]]},"reference":[{"key":"2021120906083103200_R1","unstructured":"World Health Organization. World Health Report, 2002. Annex 2. Available at: www.who.int\/whr\/2002\/en\/"},{"key":"2021120906083103200_R2","doi-asserted-by":"crossref","unstructured":"Nakayama T, Zhou J, Fujino M. Current status of measles in Japan. J Infect Chemother.\u20082003;9:1\u20137","DOI":"10.1007\/s10156-002-0206-6"},{"key":"2021120906083103200_R3","unstructured":"Measles\u2014United States 2000. MMWR Morb Mortal Wkly Rep.\u20082002;51:120\u2013123"},{"key":"2021120906083103200_R4","doi-asserted-by":"crossref","unstructured":"Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med.\u20081954;86:277\u2013286","DOI":"10.3181\/00379727-86-21073"},{"key":"2021120906083103200_R5","unstructured":"Recommendations of the Public Health Service Advisory Committee on Immunization Practice. Measles vaccine. MMWR Morb Mortal Wkly Rep.\u20081967;16:269\u2013271"},{"key":"2021120906083103200_R6","unstructured":"Strebel PM, Papania MJ, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia, PA: WB Saunders; 2003:389\u2013440"},{"key":"2021120906083103200_R7","unstructured":"American Academy of Pediatrics. Committee on Infectious Disease. Measles: reassessment of the current immunization policy. Pediatrics.\u20081989;84:1110\u20131113"},{"key":"2021120906083103200_R8","doi-asserted-by":"crossref","unstructured":"National Vaccine Advisory Committee. The measles epidemic: the problems, barriers and recommendations. JAMA.\u20081991;266:1547\u20131552","DOI":"10.1001\/jama.266.11.1547"},{"key":"2021120906083103200_R9","unstructured":"Centers for Disease Control and Prevention. Summaries of notifiable diseases in the United States, 2001. MMWR Morb Mortal Wkly Rep.\u20082003;50:1\u201321"},{"key":"2021120906083103200_R10","unstructured":"Centers for Disease Control and Prevention. Imported measles case associated with nonmedical vaccine exemption\u2014Iowa, March 2004. MMWR Morb Mortal Wkly Rep.\u20082004;53:244\u2013246"},{"key":"2021120906083103200_R11","unstructured":"Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps and rubella\u2014vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20081998;47:1\u201357"},{"key":"2021120906083103200_R12","doi-asserted-by":"crossref","unstructured":"Reyes MA, Franky De Borrero M, Roa J, et al. Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J.\u20081987;6:848\u2013851","DOI":"10.1097\/00006454-198709000-00012"},{"key":"2021120906083103200_R13","doi-asserted-by":"crossref","unstructured":"Hirose M, Hidaka Y, Miyazaki C, et al. Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination. Scand J Infect Dis.\u20081997;29:187\u2013190","DOI":"10.3109\/00365549709035882"},{"key":"2021120906083103200_R14","doi-asserted-by":"crossref","unstructured":"Mathias R, Meekison J, Arcand T, et al. The role of secondary vaccine failures in measles outbreaks. Am J Public Health.\u20081989;79:475\u2013478","DOI":"10.2105\/AJPH.79.4.475"},{"key":"2021120906083103200_R15","doi-asserted-by":"crossref","unstructured":"Duclos P, Redd SC, Varughese P, Hersh BS. Measles in adults in Canada and the U.S.: implications for measles elimination and eradication. Int J Epidemiol.\u20081999;28:141\u2013146","DOI":"10.1093\/ije\/28.1.141"},{"key":"2021120906083103200_R16","unstructured":"Supplementary statement on measles elimination in Canada. Can Commun Dis Rep.\u20081996;22:9\u201315"},{"key":"2021120906083103200_R17","doi-asserted-by":"crossref","unstructured":"Strebel P, Cochi S, Grabowsky M, et al. The unfinished measles immunization agenda. J Infect Dis.\u20082003;187:S1\u2013S7","DOI":"10.1086\/368226"},{"key":"2021120906083103200_R18","doi-asserted-by":"crossref","unstructured":"Cutts FT, Grabowsky M, Markowitz LE. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals.\u20081995;23:95\u2013106","DOI":"10.1016\/1045-1056(95)90018-7"},{"key":"2021120906083103200_R19","unstructured":"World Health Organization. Measles Technical Working Group: Strategies for Measles Control and Elimination. Report of a Meeting. Geneva, Switzerland: World Health Organization; 2001 (WHO\/V&B\/01.37)"},{"key":"2021120906083103200_R20","unstructured":"Measles Mortality Reduction and Regional Elimination Strategic Plan 2001-2005. Geneva, Switzerland: World Health Organization and United Nations Children\u2019s Fund; 2001 (WHO\/V&B\/01.13)"},{"key":"2021120906083103200_R21","unstructured":"Centers for Disease Control and Prevention (CDC). National, state, and urban area vaccination levels among children aged 19\u201335 Months\u2014United States, 2002. MMWR Morb Mortal Wkly Rep.\u20082003;52:728\u2013732"},{"key":"2021120906083103200_R22","doi-asserted-by":"crossref","unstructured":"Feikin DR, Lexotte DC, Hamman RF, Salmon DA, Chen RT, Hoffman RE. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA.\u20082000;284:3145\u20133150","DOI":"10.1001\/jama.284.24.3145"},{"key":"2021120906083103200_R23","doi-asserted-by":"crossref","unstructured":"Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws. JAMA.\u20081999;282:47\u201353","DOI":"10.1001\/jama.282.1.47"},{"key":"2021120906083103200_R24","doi-asserted-by":"crossref","unstructured":"Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lympho-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet.\u20081998;351:637\u2013641","DOI":"10.1016\/S0140-6736(97)11096-0"},{"key":"2021120906083103200_R25","doi-asserted-by":"crossref","unstructured":"Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. Lancet.\u20082004;363:750","DOI":"10.1016\/S0140-6736(04)15715-2"},{"key":"2021120906083103200_R26","doi-asserted-by":"crossref","unstructured":"Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol.\u20082002;55:84\u201390","DOI":"10.1136\/mp.55.2.84"},{"key":"2021120906083103200_R27","doi-asserted-by":"crossref","unstructured":"van den Hof S, Conyn-van Spaendonck MAE, van Steenbergen JE. Measles epidemic in The Netherlands, 1999\u20132000. J Infect Dis.\u20082002;186:1483\u20131486","DOI":"10.1086\/344894"},{"key":"2021120906083103200_R28","doi-asserted-by":"crossref","unstructured":"McBrien J, Murphy J, Gill D, Cronin M, O\u2019Donovan C, Cafferkey MT. Measles outbreak in Dublin, 2000. Pediatr Infect Dis J.\u20082003;22:580\u2013584","DOI":"10.1097\/01.inf.0000073059.57867.36"},{"key":"2021120906083103200_R29","doi-asserted-by":"crossref","unstructured":"Clarke T. Measles returns to Britain. Public fear of MMR vaccine blamed for increased outbreaks. Nature (Science Update).\u20082003;8. Available at: www.nature.com\/nsu\/030804\/030804-12.html","DOI":"10.1038\/news030804-12"},{"key":"2021120906083103200_R30","doi-asserted-by":"crossref","unstructured":"Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14 year prospective study. Lancet.\u20081998;351:1327\u20131328","DOI":"10.1016\/S0140-6736(98)24018-9"},{"key":"2021120906083103200_R31","doi-asserted-by":"crossref","unstructured":"Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet.\u20081999;353:2026\u20132029","DOI":"10.1016\/S0140-6736(99)01239-8"},{"key":"2021120906083103200_R32","doi-asserted-by":"crossref","unstructured":"Kaye JA, Melero-Montes MM, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ.\u20082001;322:460\u2013463","DOI":"10.1136\/bmj.322.7284.460"},{"key":"2021120906083103200_R33","doi-asserted-by":"crossref","unstructured":"Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA.\u20082001;285:1183\u20131185","DOI":"10.1001\/jama.285.9.1183"},{"key":"2021120906083103200_R34","doi-asserted-by":"crossref","unstructured":"Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ.\u20082002;324:393\u2013396","DOI":"10.1136\/bmj.324.7334.393"},{"key":"2021120906083103200_R35","doi-asserted-by":"crossref","unstructured":"Madsen KM, Hvid A, Vestergaard M, et al. A population based study of measles, mumps and rubella vaccination and autism. N Engl J Med.\u20082002;347:1477\u20131482","DOI":"10.1056\/NEJMoa021134"},{"key":"2021120906083103200_R36","doi-asserted-by":"crossref","unstructured":"DeStefano F, Bhason PK, Thompson WW, Allsopp MY, Boyle C. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics.\u20082004;113:259\u2013266","DOI":"10.1542\/peds.113.2.259"},{"key":"2021120906083103200_R37","unstructured":"Stratton K, Gable A, Shetty P, McCormick M. Institute of Medicine. Immunization Safety Review: Measles, Mumps, Rubella Vaccine and Autism. Washington, DC: National Academies Press; 2001:1\u201386"},{"key":"2021120906083103200_R38","doi-asserted-by":"crossref","unstructured":"Halsey NA, Hyman SL. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the new challenges in childhood immunizations conference convened in Oak Brook, Illinois, June 12\u201313, 2000. Pediatrics.\u20082001;107(5). Available at: www.pediatrics.org\/cgi\/content\/full\/107\/5\/e84","DOI":"10.1542\/peds.107.5.e84"},{"key":"2021120906083103200_R39","doi-asserted-by":"crossref","unstructured":"Fombonne E. Is there an epidemic of autism?Pediatrics.\u20082001;107:411\u2013413","DOI":"10.1542\/peds.107.2.411"},{"key":"2021120906083103200_R40","doi-asserted-by":"crossref","unstructured":"Gillberg C, Wing L. Autism: not an extremely rare disorder. Acta Psychiatr Scand.\u20081999;99:379\u2013406","DOI":"10.1111\/j.1600-0447.1999.tb00984.x"},{"key":"2021120906083103200_R41","doi-asserted-by":"crossref","unstructured":"Fombonne E. The prevalence of autism. JAMA.\u20082003;289:87\u201389","DOI":"10.1001\/jama.289.1.87"},{"key":"2021120906083103200_R42","doi-asserted-by":"crossref","unstructured":"Courchesne E, Carper R, Alkshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA.\u20082003;290:337\u2013344","DOI":"10.1001\/jama.290.3.337"},{"key":"2021120906083103200_R43","doi-asserted-by":"crossref","unstructured":"Orenstein WAS, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL. Measles eradication: is it in our future?Am J Public Health.\u20082000;90:1521\u20131525","DOI":"10.2105\/AJPH.90.10.1521"},{"key":"2021120906083103200_R44","doi-asserted-by":"crossref","unstructured":"Permar SR, Moss WJ, Ryon JJ, et al. Prolonged measles virus shedding in HIV infected children, detected by reverse PCR reaction. J Infect Dis.\u20082001;183:532\u2013538","DOI":"10.1086\/318533"},{"key":"2021120906083103200_R45","unstructured":"Pan American Health Organization. PAHO Announces Drive to Eliminate Rubella. (Press release on September 22, 2003). Available at: www.paho.org\/English\/DD\/PIN\/pr030922c.htm"},{"key":"2021120906083103200_R46","doi-asserted-by":"crossref","unstructured":"Miller MA, Redds, Hadler S, Hinman A. A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine.\u20081998;16:1917\u20131922","DOI":"10.1016\/S0264-410X(98)00125-X"},{"key":"2021120906083103200_R47","doi-asserted-by":"crossref","unstructured":"Carabin H, Edmunds WJ. Future savings from measles eradication in industrialized countries. J Inf Dis.\u20082003;187:S29\u2013S35","DOI":"10.1086\/368038"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/4\/1065\/1020082\/zpe01004001065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/4\/1065\/1020082\/zpe01004001065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:21:54Z","timestamp":1639095714000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/4\/1065\/73276\/Measles-Vaccines-and-the-Potential-for-Worldwide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,1]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,10,1]]},"published-print":{"date-parts":[[2004,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-0440","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,1]]}}}